UNAIDS. Global AIDSUpdate 2016. Geneva, Switzerland. Available from: https://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016. Accessed 15 Aug 2018.
Joint United Nations Programme on HIV/AIDS. Fact sheet—Latest statistics on the status of the AIDS epidemic. 2017. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed 20 Aug 2018.
CSA.Ethiopia Demographic and Health Survey. HIV prevalence report. Central Statistical Authority. 2016;2016.
Yared M, Tibebu S, Emmart P. Equity and access to ART in Ethiopia. Washington, DC: Future Group, Health Policy Initiative. Task Order I; 2010.
Google Scholar
Assefa Y, Jerene D, Lulseged S, Ooms G, Van Damme W. Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects. PLoS Med. 2009;6:e1000056.
Article
PubMed
PubMed Central
CAS
Google Scholar
Federal Ministry of Health. Ethiopian National consolidated guidelines for comprehensive HIV prevention, care and treatment. 2018. Available from: https://aidsfree.usaid.gov/resources/ethiopia-national-guidelines-comprehensive-hiv-prevention-care-and-treatment-0. Accessed 10 Aug 2018.
Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother. 2009;64:239–50.
Article
CAS
PubMed
Google Scholar
Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–90.
Article
CAS
PubMed
Google Scholar
Park WB, Choe PG, Kim S-H, Jo JH, Bang JH, Kim HB, Kim NJ, Oh M-D, Choe KW. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Res Hum Retrovir. 2007;23:794–800.
Article
CAS
PubMed
Google Scholar
Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in human immunodeficiency virus–infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170:57–65.
Article
CAS
PubMed
Google Scholar
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S. Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. JAIDS. 2008;47:206–11.
CAS
PubMed
Google Scholar
Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med. 2007;8:186–91.
Article
CAS
PubMed
Google Scholar
Timothy W, Marshall G, Roy M. HIV insight knowledge base chapter changing antiretroviral therapy: why, when and how. JAIDS. 2006;12:782–9.
Google Scholar
Rappold M, Rieger A, Steuer A, Geit M, Sarcletti M, Haas B, Taylor N, Kanatschnig M, Leierer G, Ledergerber B. Treatment modification in HIV-infected individuals starting antiretroviral therapy between 2011 and 2014. J Int AIDS Society. 2014;17.
Article
PubMed
PubMed Central
Google Scholar
Jima YT, Angamo MT, Wabe N-T. Causes for antiretroviral regimen change among HIV/AIDS patients in Addis Ababa. Ethiopia Tanzania J Health Res. 2013;15:11.
Google Scholar
Blanco J, Clotet B. Learning from drug changes in antiretroviral therapy. AIDS. 2013;27:833–4.
Article
PubMed
Google Scholar
Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. JAIDS. 2007;45:218–23.
PubMed
Google Scholar
Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. The Lancet .2006; 368:505–510.
Article
Google Scholar
WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. Geneva: World Health Organization; 2010. Available from: https://www.who.int/hiv/pub/arv/adult2010/en/. Accessed 23 July 2018.
Frehiwot N, Mizan K, Seble M, Fethia K, Tekalign M, Zelalem T. National guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa Ministry of Health. 2014.
Church K, Kiweewa F, Dasgupta A, Mwangome M, Mpandaguta E, Gómez-Olivé FX, Oti S, Todd J, Wringe A, Geubbels E. A comparative analysis of national HIV policies in six African countries with generalized epidemics. Bull World Health Organ. 2015;93:457–67.
Article
PubMed
PubMed Central
Google Scholar
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016. Available from: https://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed 12 Aug 2018.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
Article
PubMed
PubMed Central
Google Scholar
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based healthcare. 2015;13:147–53.
Article
Google Scholar
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994:1088–101.
Article
CAS
PubMed
Google Scholar
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zeleke A. Prevalence of antiretroviral treatment failure and associated factors in HIV infected children on antiretroviral therapy at Gondar University hospital, retrospective cohort study. Int J Med Med Sci. 2016;8:125–32.
Article
Google Scholar
Sisay MM, Ayele TA, Gelaw YA, Tsegaye AT, Gelaye KA, Melak MF. Incidence and risk factors of first-line antiretroviral treatment failure among human immunodeficiency virus-infected children in Amhara regional state. Ethiopia: a retrospective follow-up study BMJ open. 2018;8:e019181.
PubMed
Google Scholar
Tadesse BT, Foster BA, Jerene D, Ruff A. Cohort profile: improving treatment of HIV-infected Ethiopian children through better detection of treatment failure in southern Ethiopia. BMJ Open. 2017;7:e013528.
Article
PubMed
PubMed Central
Google Scholar
Yassin S, Gebretekle GB. Magnitude and predictors of antiretroviral treatment failure among HIV-infected children in fiche and Kuyu hospitals, Oromia region, Ethiopia: a retrospective cohort study. Pharmacol Res Perspect. 2017;5(1):e00296.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wube M, Tesfaye A, Hawaze S. Antiretroviral therapy regimen change among HIV/AIDS patients in Nekemt hospital: a primary Care Hospital in Oromia Regional State, Ethiopia. J App Pharm Sci .2013; 3(08):036–040.
Anlay DZ, Alemayehu ZA, Dachew BA. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study. AIDS Res Ther. 2016;13:10.
Article
PubMed
PubMed Central
CAS
Google Scholar
Addisalem G, Messay W-M. Assessment of highly active antiretroviral therapy outcomes among HIV infected adult patients in Jimma university specialized hospital, Jimma, south West Ethiopia. Med Data. 2014;6(3):211–8.
Google Scholar
Mulugeta A, Chanie T. Cause of antiretroviral drug changes among patients on antiretroviral therapy at the art center in Dessei regional referral hospital. Ethiopia Int J Pharm Sci Res. 2012;3:120.
CAS
Google Scholar
Assefa D, Hussein N. Reasons for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in Fitche hospital, Oromia. Ethiopia Adv Pharmacol Pharm. 2014;2:77–83.
Google Scholar
Mekonnen Y, Molla G. Reason for regimen change among HIV patients on initial highly active ARV therapy in Bedele hospital ART clinic. Ethiopia J Biotechnol Biosafety. 2014;2:116–22.
Google Scholar
Haile D, Takele A, Gashaw K, Demelash H, Nigatu D. Predictors of treatment failure among adult antiretroviral treatment (ART) clients in bale zone hospitals. South Eastern Ethiopia PloS one. 2016;11:e0164299.
Article
PubMed
CAS
Google Scholar
Tadesse WT, Mekonnen AB, Tesfaye WH, Tadesse YT. Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol. 2014;15:32.
Article
PubMed
PubMed Central
CAS
Google Scholar
Birlie B, Braekers R, Awoke T, Kasim A, Shkedy Z. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. BMC Infect Dis. 2017;17.
Bokore A, Korme B, Bayisa G. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, West Ethiopia: a cross-sectional study. BMC Pharmacol Toxicol. 2018;19:28.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mekonnen E, Workicho A, Hussein N, Feyera T. Reasons and predictors for antiretroviral therapy change among HIV-infected adults at south West Ethiopia. BMC Res Note. 2018;11:351.
Article
Google Scholar
Eshetu B, Wencheko E. Survival longevity of adult AIDS patients under ART: a case study at Felege Hiwot referral hospital, Bahir Dar. Ethiopia Ethiop J Health Dev. 2014;28(2):105–15.
Google Scholar
Kasu B, Zeleke G, Gashe F. The reasons for regimen shift among people living with HIV/AIDS in Asella referral hospital. Medicine. 2017;6:625–8.
Google Scholar
Gebremedhin L, Birhane A. Reasons for anti-retroviral regimen changes in HIV/AIDS patients of Ayder referral hospital ART clinic, Mekelle. Ethiopia Int J Pharma Sci Res. 2014;5:693–700.
CAS
Google Scholar
Teklay G, Legesse B, Legesse M. Adverse effects and regimen switch among patients on antiretroviral treatment in a resource limited setting in Ethiopia. Aust J Pharm. 2013;1:115.
Google Scholar
Woldemedhin B, Wabe NT. The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in southern Ethiopia. North American J Med Sci. 2012;4:19.
Article
Google Scholar
ATC Collaboration. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013;27:803–13.
Google Scholar
Keiser O, Orrell C, Egger M, Wood R, Brinkhof M, Furrer H, Van Cutsem G, Ledergerber B, Boulle A. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med. 2008;5.
Article
PubMed Central
Google Scholar
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49–62.
Article
PubMed
Google Scholar
Sivadasan A, Abraham O, Rupali P, Pulimood SA, Rajan J, Rajkumar S, Zachariah A, Kannangai R, Kandathip A, Sridharan G. High rates of regimen change due to drug toxicity among a cohort of south Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India. 2009;57:384–8.
PubMed
Google Scholar
Monforte AA, Lepri AC. Rezza G, Pezzotti P, Antinori a, Phillips AN, Angarano G, Colangeli V, De Luca a, Ippolito G. insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14:499–507.
Article
Google Scholar
Wilkin T, Glesby M, Gulick RM. Switching antiretroviral therapy: why, when and how. IAPAC monthly. 2006;12:220.
PubMed
Google Scholar
Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society–USA panel. JAMA. 2014;312:410–25.
Article
PubMed
CAS
Google Scholar
UNAIDS. 90‐90‐90, on the right track towards the global target. 2016. Geneva, Switzerland. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/90_90_90_Progress_ReportFINAL.pdf. Accessed 26 Aug 2018.
Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De PL, Lo SC, Narciso P, Pauluzzi S, Carosi G. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. JAIDS. 2001;28:445–9.
CAS
PubMed
Google Scholar
Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One. 2010;5:e10490.
Article
PubMed
PubMed Central
CAS
Google Scholar
O’brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. JAIDS. 2003;34:407–14.
PubMed
Google Scholar
Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, Fontanet A, Katlama C, Madec Y. Switch to second-line ART in west African routine care: incidence and reasons for switching. AIDS Care. 2011;23:75–8.
Article
PubMed
Google Scholar
Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21:1301–8.
Article
PubMed
Google Scholar
Hill S, Kavookjian J, Qian J, Chung A, Vandewaa J. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden. AIDS Care. 2014;26:595–601.
Article
PubMed
Google Scholar
Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4:459.
Article
PubMed
PubMed Central
Google Scholar
Cozzi-Lepri A, Paredes R, Phillips A, Clotet B, Kjær J, Von Wyl V, Kronborg G, Castagna A, Bogner J, Lundgren J. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med. 2012;13:62–72.
CAS
PubMed
Google Scholar
Pillay D, Kityo C, Robertson V, Lyagoba F, Dunn D, Tugume S. Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of combivir/tenofovir within the DART trial. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Poster 642.
Federal Ministry of Health. Guidelines for use of antiretroviral drugs in Ethiopia. Addis Ababa: Federal Ministry of Health; 2005.
Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301–4.
Article
CAS
PubMed
Google Scholar